Foghorn Therapeutics Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
Employees
106
IPO date
Oct 23, 2020

Foghorn Therapeutics is a drug discovery company that tries to make medicines by targeting the chromatin regulatory system, the set of proteins that helps control which genes turn on and off in cells. In plain terms, it looks for weak points in the way cancer cells and other diseased cells manage gene activity, then designs small-molecule drugs to disrupt those weak points. Its work is still centered on research and clinical development rather than selling approved medicines at scale.

The company’s main customers are not patients directly, but pharmaceutical partners, hospitals, doctors, and ultimately patients if its drug candidates are approved. Foghorn can make money in a few ways: by advancing its own drug pipeline, by signing research or licensing deals with larger drug companies, and potentially by earning future sales or milestone payments if its medicines reach the market. Today, most of its value comes from developing and testing its own experimental therapies.

What makes Foghorn different is its focus on the biology that sits behind gene control, rather than on a single disease pathway or a traditional antibody approach. That gives it a platform-style role in drug discovery: if its science works, the same underlying method can be used to find treatments for several diseases, especially cancers that depend on abnormal gene regulation. This makes it a specialized biotech with a science-driven, high-risk, long-development business model.

Foghorn Therapeutics Inc Investor Relations

Address
500 Technology Square, Suite 700
Cambridge, Massachusetts
United States of America

Business Segments

Drug discovery and development

Foghorn Therapeutics discovers and develops medicines that target the chromatin regulatory system, which helps control how genes turn on and off in cells. The company advances these drug candidates through research, lab...

Customers and revenue model

Management

Mr. Adrian H. B. Gottschalk

President, CEO & Director

Biography unavailable

Dr. Steven F. Bellon Ph.D.

Chief Scientific Officer

Biography unavailable

Dr. Alfonso Quintas Cardama M.D.

Chief Medical Officer

Biography unavailable

Dr. Gerald R. Crabtree M.d.

Founder & Member of Scientific Advisory Board

Biography unavailable

Mr. Kristian Humer M.B.A.

Chief Financial Officer

Biography unavailable

Ms. Karin Hellsvik

Chief of Staff to the CEO, VP of Corporate Affairs & Investor Relations

Biography unavailable

Mr. Michael J. LaCascia J.D.

Chief Legal Officer

Biography unavailable

Mr. Saurabh Sewak Ph.D.

Vice President of Corporate Development

Biography unavailable

Mr. Carlos Costa

Chief People Officer

Biography unavailable

Dr. Anna Rivkin Ph.D.

Chief Business Officer

Biography unavailable

1 / 10